Iron Horse Diagnostics, Inc. is a privately held molecular diagnostic company focused on the development and commercialization of novel tests to support the diagnosis and management of amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), and other neurological diseases.
Iron Horse has developed and validated assays to measure protein-based signatures of disease. We expect to launch our first diagnostic test from a central reference laboratory in late 2015. This diagnostic is for ALS and uses cerebrospinal fluid samples. Our next product will be a blood-based diagnostic for ALS, with additional prognostic assays for ALS that can be used to monitor disease progression and test the effectiveness of drugs in clinical trials. Follow-up blood-based diagnostic assays will be for TBI and neuronal injury.